Fouad Alchami

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

Robert H. Jones, Angela Casbard, Margherita Carucci et al. · The Lancet Oncology · 2020 · 220 citations · Full text

Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study

Lauren Rosen, Theodore Karrison, Vijayalakshmi Ananthanarayanan et al. · Modern Pathology · 2018 · 95 citations · Full text

Tumoral Pathology, Medicine, Surgical Pathology +7

Synergistic targeting of breast cancer stem‐like cells by human γδ T cells and CD8⁺ T cells

Hung‐Chang Chen, Noémie Joalland, John S. Bridgeman et al. · Immunology and Cell Biology · 2017 · 61 citations · Full text

Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP

Luke Piggott, Andreia Silva, Tim Robinson et al. · Clinical Cancer Research · 2018 · 54 citations · Full text

Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial.

Robert H. Jones, Margherita Carucci, Angela Casbard et al. · Journal of Clinical Oncology · 2019 · 38 citations

Breast Oncology, Oncology, Phase Ii Trial +13